Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature

Clinical Cancer Research

Volumn 11, Issue 17, 2005, Pages 6317-6324

  Kessler, Torsten ^a   Bieker, Ralf ^a   Padró, Teresa ^a   Schwöppe, Christian ^a   Persigehl, Thorsten ^a   Bremer, Christoph ^a   Kreuter, Michael ^a   Berdel, Wolfgang E ^a   Mesters, Rolf M ^a,b  

^a IZKF Muenster ^*  (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CD51 ANTIGEN; GLYCYLARGINYLGLYCYLASPARTYLSERYLPROLINE; HYBRID PROTEIN; THROMBOPLASTIN; TRUNCATED THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; CELL STRAIN; CELL STRAIN CCL185; CELL STRAIN HT1080; CELL STRAIN M21; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTRATUMORAL DRUG ADMINISTRATION; MALE; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BINDING; RETICULOENDOTHELIAL SYSTEM; THROMBOGENICITY; THROMBOSIS; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR NECROSIS; TUMOR THROMBUS; TUMOR VASCULARIZATION;

ANIMALS; BLOOD FLOW VELOCITY; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; THROMBOPLASTIN;

EID: 24344462235     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0389     Document Type: Article

References (48)

1. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44.
4. Bieker R, Padro T, Kramer J, et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 2003;63: 7241-6.
5. Carnemolla B, Balza E, Siri A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989;108:1139-48.
6. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991;174:1275-8.
7. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Upregulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995;1:1623-34.
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
9. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A 1992;89:10832-6.
10. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
11. 1 integrins. Proc Natl Acad Sci USA 1997;94:13612-7.
12. Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 1997;73:865-70.
13. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
14. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A 2000;97:12227-32.
15. Kessler TA, Pfeifer A, Silletti S, et al. Matrix metalloproteinase/ integrin interactions as target for anti-angiogenic treatment strategies. Ann Hematol 2002; 81 Suppl 2:S69-70.
16. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.
17. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-50.
18. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998;58:4646-53.
19. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-6.
20. Liu C, Huang H, Donate F, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002;62:5470-5.
21. Hu P, Van J, Sharifi J, Bai T, Khawli LA, Epstein AL. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res 2003;63:5046-53.
22. Topp MS, Koenigsmann M, Mire-Sluis A, et al. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 1993;82:2837-44.
23. v gene expression in human melanoma tumorigenicity. J Clin Invest 1992;89:2018-22.
24. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991;266:16256.
25. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A 2001;98:119-24.
26. Bremer C, Mustafa M, Bogdanov A Jr, Ntziachristos V, Petrovsky A, Weissleder R. Steady-state blood volume measurements in experimental tumors with different angiogenic burdens: a study in mice. Radiology 2003;226:214-20.
27. Junker K, Thomas M, Schulmann K, Klinke V, Bosse U, Muller KM. Regression grading of neoadjuvant non-small-cell lung carcinoma treatment. Pathologe 1997;18:131-40.
28. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
29. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000;10:435-42.
30. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
31. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999;59:2869-74.
32. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor α anti-tumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90.
33. Boger DL, Goldberg J, Silletti S, Kessler T, Cheresh DA. Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin α(V)β(3). J Am Chem Soc 2001;123:1280-8.
34. 3 for angiogenesis. Science 1994;264:569-71.
35. v integrins. Cell 1998;95:507-19.
36. 5 integrins. Nat Med 2002;8:27-34.
37. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor Vlla with soluble tissue factor. Nature 1996;380:41-6.
38. Stone MJ, Ruf W, Miles DJ, Edgington TS, Wright PE. Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization. Biochem J 1995;310:605-14.
39. 1 integrin from phage display library. J Biol Chem 1993;268:20205-10.
40. Bevers EM, Rosing J, Zwaal RF. Development of procoagulant binding sites on the platelet surface. Adv Exp Med Biol 1985;192:359-71.
41. Dachary-Prigent J, Toti F, Satta N, Pasquet JM, Uzan A, Freyssinet JM. Physiopathological significance of catalytic phospholipids in the generation of thrombin. Semin Thromb Hemost 1996;22:157-64.
42. Ortel TL, Quinn-Allen MA, Charles LA, Devore-Carter D, Kane WH. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. J Clin Invest 1992;90:2340-7.
43. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 2003;1613: 115-21.
44. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81:734-44.
45. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 1991;77:75-83.
46. 3 and platelet function. Thromb Haemost 1997;78:96-100.
47. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:2645-57.
48. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983;736:57-66.